Literature DB >> 6755168

The hypercalcemia of malignancy: pathogenesis and management.

G R Mundy, T J Martin.   

Abstract

The number of agents and treatment regimens which can be used in the medical treatment of hypercalcemia has increased markedly over the last 5 yr. As this list has increased, clinicians are anxious to know more about the humoral and cellular mechanisms which are responsible for the hypercalcemia of malignancy and to understand how these drugs work. Unfortunately there is no treatment available presently which is uniformally safe and effective, and the potential pathogenetic mechanisms responsible for hypercalcemia are hotly debated. In this review, we plan to summarize current views of the pathogenesis, clinical features and treatment of hypercalcemia associated with malignant disease.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6755168     DOI: 10.1016/0026-0495(82)90012-9

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  48 in total

1.  Percutaneus osteoplasty in the treatment of extraspinal painful multiple myeloma lesions.

Authors:  Salvatore Masala; Tommaso Volpi; Francesco P M Fucci; Maria Cantonetti; Massimiliano Postorino; Giovanni Simonetti
Journal:  Support Care Cancer       Date:  2010-05-27       Impact factor: 3.603

2.  Effect of salmon calcitonin and etidronate on hypercalcemia of malignancy.

Authors:  S Fatemi; F R Singer; R K Rude
Journal:  Calcif Tissue Int       Date:  1992-02       Impact factor: 4.333

Review 3.  Incidence and pathophysiology of hypercalcemia.

Authors:  G R Mundy
Journal:  Calcif Tissue Int       Date:  1990       Impact factor: 4.333

4.  Clinical significance of natural killing activity in patients with advanced lymphoma.

Authors:  K Ono
Journal:  J Clin Immunol       Date:  1998-03       Impact factor: 8.317

5.  Renal handling of calcium and sodium in metastatic and non-metastatic malignancy.

Authors:  S R Heller; D J Hosking
Journal:  Br Med J (Clin Res Ed)       Date:  1986-03-01

Review 6.  The pathobiology of the osteoclast.

Authors:  T J Chambers
Journal:  J Clin Pathol       Date:  1985-03       Impact factor: 3.411

7.  Relative contribution of humoral and metastatic factors to the pathogenesis of hypercalcaemia in malignancy.

Authors:  S H Ralston; I Fogelman; M D Gardiner; I T Boyle
Journal:  Br Med J (Clin Res Ed)       Date:  1984-05-12

8.  Cloacogenic anal carcinoma presenting with humoral hypercalcemia: report of a case.

Authors:  S Nobusawa; S Sato; A Matsumoto; T Yamada; N Tanaka
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

Review 9.  Hypercalcaemia of malignancy.

Authors:  P J Kelly; J A Eisman
Journal:  Cancer Metastasis Rev       Date:  1989-06       Impact factor: 9.264

10.  Quantitation of the renal effect of calcitonin in the hypercalcaemia of malignancy.

Authors:  D J Hosking; S R Heller
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.